Short Interest in Replimune Group, Inc. (NASDAQ:REPL) Grows By 16.7%

Replimune Group, Inc. (NASDAQ:REPL) saw a significant growth in short interest in the month of January. As of January 31st, there was short interest totalling 8,470,000 shares, a growth of 16.7% from the January 15th total of 7,260,000 shares. Based on an average daily trading volume, of 885,200 shares, the days-to-cover ratio is presently 9.6 days.

Insider Activity

In other news, CEO Sushil Patel sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $12.42, for a total value of $124,200.00. Following the completion of the transaction, the chief executive officer now owns 202,014 shares in the company, valued at $2,509,013.88. This represents a 4.72 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Konstantinos Xynos sold 7,246 shares of the company’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $10.78, for a total transaction of $78,111.88. Following the completion of the transaction, the insider now owns 109,885 shares of the company’s stock, valued at $1,184,560.30. This trade represents a 6.19 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 8.80% of the company’s stock.

Hedge Funds Weigh In On Replimune Group

Large investors have recently modified their holdings of the stock. Sterling Capital Management LLC raised its position in shares of Replimune Group by 364.5% in the fourth quarter. Sterling Capital Management LLC now owns 2,109 shares of the company’s stock valued at $26,000 after purchasing an additional 1,655 shares during the period. Tower Research Capital LLC TRC raised its position in shares of Replimune Group by 696.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company’s stock valued at $82,000 after purchasing an additional 5,922 shares during the period. Aster Capital Management DIFC Ltd raised its position in shares of Replimune Group by 8,798.9% in the fourth quarter. Aster Capital Management DIFC Ltd now owns 8,276 shares of the company’s stock valued at $100,000 after purchasing an additional 8,183 shares during the period. Erste Asset Management GmbH bought a new position in shares of Replimune Group in the third quarter valued at about $133,000. Finally, XTX Topco Ltd bought a new position in shares of Replimune Group in the fourth quarter valued at about $137,000. 92.53% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have recently commented on REPL shares. Jefferies Financial Group boosted their price objective on shares of Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, December 4th. HC Wainwright boosted their price objective on shares of Replimune Group from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, BMO Capital Markets boosted their price objective on shares of Replimune Group from $18.00 to $27.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 22nd. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Replimune Group has an average rating of “Buy” and a consensus price target of $19.29.

Replimune Group Trading Down 1.3 %

NASDAQ REPL traded down $0.19 on Friday, hitting $14.10. 431,744 shares of the stock were exchanged, compared to its average volume of 790,791. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.11 and a current ratio of 10.11. The business’s fifty day moving average is $12.54 and its 200 day moving average is $11.73. Replimune Group has a 52 week low of $4.92 and a 52 week high of $17.00.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.09). On average, analysts anticipate that Replimune Group will post -2.88 earnings per share for the current year.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.